Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malcolm A Smith

Showing results (71-80 of 188) with videos related to

Pageof 19
Sort By:
Pediatric Blood & Cancer|March 25, 2020
Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing ConsortiumDouglas J Harrison, Jonathan D Gill, Michael E Roth, et al.
Pediatric Blood & Cancer|July 31, 2010
Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing programStephen T Keir, John M Maris, Richard Lock, et al.
Pediatric Blood & Cancer|February 8, 2011
Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, Richard Lock, et al.
Pediatric Blood & Cancer|May 7, 2009
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing programNino Keshelava, Peter J Houghton, Christopher L Morton, et al.
Molecular Cancer Therapeutics|June 10, 2021
International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with CancerGilles Vassal, Peter J Houghton, Stefan M Pfister, et al.
Pediatric Blood & Cancer|November 5, 2011
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signalingE Anders Kolb, Richard Gorlick, Stephen T Keir, et al.
Pediatric Blood & Cancer|October 28, 2016
Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing ProgramRaushan T Kurmasheva, Richard Gorlick, E Anders Kolb, et al.
Pediatric Blood & Cancer|May 7, 2009
Initial testing of aplidin by the pediatric pre-clinical testing programChristopher L Morton, Peter J Houghton, Richard Gorlick, et al.
JCI Insight|April 29, 2016
Synergism of FAK and tyrosine kinase inhibition in Ph<sup>+</sup> B-ALLMichelle L Churchman, Kathryn Evans, Jennifer Richmond, et al.
Pediatric Blood & Cancer|January 29, 2010
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)John M Maris, Christopher L Morton, Richard Gorlick, et al.
Pageof 19

Showing results (71-80 of 188) with videos related to

Sort By:
Pageof 19
Pediatric Blood & Cancer|March 25, 2020
Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing ConsortiumDouglas J Harrison, Jonathan D Gill, Michael E Roth, et al.
Pediatric Blood & Cancer|July 31, 2010
Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing programStephen T Keir, John M Maris, Richard Lock, et al.
Pediatric Blood & Cancer|February 8, 2011
Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, Richard Lock, et al.
Pediatric Blood & Cancer|May 7, 2009
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing programNino Keshelava, Peter J Houghton, Christopher L Morton, et al.
Molecular Cancer Therapeutics|June 10, 2021
International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with CancerGilles Vassal, Peter J Houghton, Stefan M Pfister, et al.
Pediatric Blood & Cancer|November 5, 2011
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signalingE Anders Kolb, Richard Gorlick, Stephen T Keir, et al.
Pediatric Blood & Cancer|October 28, 2016
Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing ProgramRaushan T Kurmasheva, Richard Gorlick, E Anders Kolb, et al.
Pediatric Blood & Cancer|May 7, 2009
Initial testing of aplidin by the pediatric pre-clinical testing programChristopher L Morton, Peter J Houghton, Richard Gorlick, et al.
JCI Insight|April 29, 2016
Synergism of FAK and tyrosine kinase inhibition in Ph<sup>+</sup> B-ALLMichelle L Churchman, Kathryn Evans, Jennifer Richmond, et al.
Pediatric Blood & Cancer|January 29, 2010
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)John M Maris, Christopher L Morton, Richard Gorlick, et al.
Pageof 19